TScan Therapeutics, Inc.

NASDAQ:TCRX

Biotechnology

Healthcare
$0.82 +2.23%

+$0.02 today

Market cap
$50.37M
Beta
1.03
P/E (TTM)
-1.0
EPS (TTM)
-$0.96
52W Low $0.85High $2.57

Volume 0.00M

Average 0.81M

TCRX Total Non-current Liabilities

All obligations due after more than one year.

TScan Therapeutics, Inc.NASDAQ: TCRX

Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026

Total non-current liabilities falls 8.2% from a year ago

Total non-current liabilities stood at $85.1M at the end of Q1 FY2026, down 8.2% from a year earlier and down 2.2% from the prior quarter. Over 3 fiscal years it compounded at +1.8% a year.

Context

  • Total non-current liabilities amounted to 42.1% of total assets at the end of Q1 FY2026, up 14.3 pp from a year earlier.
  • Total non-current liabilities increased in 2 of the last 3 fiscal years.

What to watch

Whether total non-current liabilities keeps falling in the next quarterly balance sheet after a -8.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$85.1M-2.2% QoQ
Last fiscal yearDec 2025
$86.97M-7.7% YoY
Year agoMar 2025
$92.69M-8.2% since
Total Non-current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-8.2%——
1 year-7.7%——
3-year CAGR+1.8%——
5-year CAGR——
10-year CAGR——

Total Non-current Liabilities history

USD · from the balance sheet

Latest · FY2025
86.97M USD
Year-over-year change
-7.7%
4-year CAGR
+95.2%

Total Non-current Liabilities vs competitors

How TCRX compares with its peers on the latest reported figures

  • TCRX's Mar 2026 total non-current liabilities of $85.1M is the highest of the 10 companies compared; the peer median is $1.82M.
  • Its year-over-year change of -8.2% is the 3rd highest of 10, against a peer median of -30.5%.
  • Total non-current liabilities amounts to 42.1% of total assets for TCRX, versus a peer median of 1.3%.
TCRX Competitors Peer median
Total Non-current Liabilities for TCRX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
TCRXTScan Therapeutics, Inc.Mar 2026$85.1M -8.2%+1.8%42.1%
FBIOFortress Biotech, Inc.Mar 2026$51.11M -28.9%-14.2%14.3%
ACETAdicet Bio, Inc.Mar 2026$11.02M -17.6%-14.6%6.5%
VXRTVaxart, Inc.Mar 2026$9.1M -37.0%-23.1%5.1%
RLMDRelmada Therapeutics, Inc.Mar 2026$3.74M +49714.6%—1.6%
XBITXBiotech Inc.Mar 2026$1.82M +4.5%+3.3%1.3%
ACRVAcrivon Therapeutics, Inc. Common StockMar 2026$1.26M -47.6%-28.7%1.2%
IMUXImmunic, Inc.Mar 2026$146K -30.5%-52.4%0.1%
NTRBNutriband Inc.Apr 2026$70.18K -43.3%-14.5%1.0%
PMVPPMV Pharmaceuticals, Inc.Mar 2026$0 -100.0%-68.1%0.0%
Peer median (excluding TCRX) $1.82M-30.5%-18.8%1.3%

Competitors are the stored peer set for TCRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents161.41M120.03M133.36M178.69M152.41M
Short-term Investments0058.69M111.42M0
Net Receivables00000
Inventory00000
Other Current Assets4.25M4.1M2.19M2.61M4.8M
Total Current Assets165.65M124.13M194.24M292.72M157.21M
Property, Plant & Equipment (Net)17.26M69.2M71.23M71.6M66.45M
Goodwill00000
Intangible Assets00000
Long-term Investments5.2M5.04M005.03M
Tax Assets000015.78M
Other Non-current Assets5.2M725K6.68M6.8M(15.67M)
Total Non-current Assets22.45M74.96M77.91M78.4M71.58M
Total Assets188.11M199.09M272.15M371.12M228.79M
Account Payables1.77M2.91M2.37M4.28M1.24M
Short-term Debt1.65M3.68M3.35M00
Tax Payables00000
Deferred Revenue11.41M3.87M10.14M11.7M2.62M
Other Current Liabilities3.92M2.48M5.9M6.92M4.34M
Total Current Liabilities21.34M17.31M29.82M35.96M18.7M
Long-term Debt029.29M26.7M32.07M32.53M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)1.5M05.62M1.25M0
Other Non-current Liabilities97K49K(1)135K0
Total Non-current Liabilities5.99M82.35M91.46M94.19M86.97M
Total Liabilities27.33M99.66M121.28M130.15M105.67M
Common Stock3K3K5K6K5K
Retained Earnings(92.16M)(158.38M)(247.6M)(375.1M)(504.86M)
Accumulated OCI00051K0
Other Stockholders Equity00000
Minority Interest00000
Total Equity160.78M99.43M150.87M240.97M123.12M
Total Debt6.04M85.98M92.43M97.38M94.14M
Net Debt(155.36M)(34.04M)(40.93M)(81.31M)(58.27M)

TScan Therapeutics, Inc.

NASDAQ:TCRX

Intrinsic Alpha fair value

Locked

Current Price

$0.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.